Trial
NCT06388889
Phase III Long-Term Extension Study With Dexpramipexole
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Areteia Therapeutics
Collaborators
—
Condition
Eosinophilic Asthma
Intervention
Dexpramipexole Dihydrochloride
Why stopped
Program stopped due to the benefit risk profile no longer supports further development in the intended patient population.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-15